These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 1329422)

  • 1. Clinical significance of the venous occlusion test on systemic lupus erythematosus patients with a focus on changes in blood levels of tissue plasminogen activator, von Willebrand factor antigen, and thrombomodulin.
    Matsuda J; Kawasugi K; Gohchi K; Saitoh N; Tsukamoto M; Kazama M; Kinoshita T
    Acta Haematol; 1992; 88(1):22-6. PubMed ID: 1329422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of total-body cold exposure on plasma concentrations of von Willebrand factor, endothelin-1 and thrombomodulin in systemic lupus erythematosus patients with or without Raynaud's phenomenon.
    Matsuda J; Tsukamoto M; Gohchi K; Saitoh N; Miyajima Y; Kazama M
    Acta Haematol; 1992; 88(4):189-93. PubMed ID: 1337960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endothelial cell activation in cutaneous vasculitis.
    Jurd KM; Stephens CJ; Black MM; Hunt BJ
    Clin Exp Dermatol; 1996 Jan; 21(1):28-32. PubMed ID: 8689765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating thrombomodulin as a novel endothelial cell marker: comparison of its behavior with von Willebrand factor and tissue-type plasminogen activator.
    Takahashi H; Ito S; Hanano M; Wada K; Niwano H; Seki Y; Shibata A
    Am J Hematol; 1992 Sep; 41(1):32-9. PubMed ID: 1323930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endothelial-dependent fibrinolysis in subjects with the lupus anticoagulant and thrombosis.
    Francis RB; McGehee WG; Feinstein DI
    Thromb Haemost; 1988 Jun; 59(3):412-4. PubMed ID: 3142079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Regulation of coagulo-fibrinolytic activity and lupus anticoagulants in systemic lupus erythematosus].
    Fusegawa H; Ichikawa Y; Tanaka Y; Shiba T; Kawada T; Shimizu H; Moriuchi J; Arimori S; Ando Y
    Ryumachi; 1990 Apr; 30(2):90-8. PubMed ID: 2122531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Thrombomodulin, von Willebrand factor and tissue plasminogen activator in the blood plasma of obese women and men].
    Rość D; Drewniak W; Kinasz-Rózycka I; Kulwas A; Michalski A
    Pol Merkur Lekarski; 2003 Dec; 15(90):518-20. PubMed ID: 15058251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disturbances in the tissue plasminogen activator/plasminogen activator inhibitor (TPA/PAI) system in systemic lupus erythematosus.
    Ruiz-Argüelles GJ; Ruiz-Argüelles A; Lobato-Mendizábal E; Díaz-Gomez F; Pacheco-Pantoja E; Drenkard C; Alarcón-Segovia D
    Am J Hematol; 1991 May; 37(1):9-13. PubMed ID: 1902623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The association of von Willebrand factor and von Willebrand factor-cleaving protease in systemic lupus erythematosus].
    Lu GY; Guo XF; Wang ZY; Bai X; Su J; Ruan CG
    Zhonghua Nei Ke Za Zhi; 2006 Jan; 45(1):42-4. PubMed ID: 16624087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abnormal plasma fibrinolysis in patients with rheumatoid arthritis and impaired endothelial fibrinolytic response in those complicated by vasculitis.
    Lau CS; McLaren M; Hanslip J; Kerr M; Belch JJ
    Ann Rheum Dis; 1993 Sep; 52(9):643-9. PubMed ID: 8239758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secretory response of the vessel wall to DDAVP and venous occlusion in von Willebrand's disease.
    Bykowska K; Letowska M; Sabliński J; Binder BR; Kopeć M; Lopaciuk S
    Acta Haematol Pol; 1994; 25(3):261-8. PubMed ID: 7992599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of enhanced thromboxane biosynthesis in patients with systemic lupus erythematosus.
    Ferro D; Basili S; Roccaforte S; Di Franco M; Cipollone F; Ciabattoni G; Davì G
    Arthritis Rheum; 1999 Dec; 42(12):2689-97. PubMed ID: 10616019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibrinolysis and coagulation abnormalities in systemic lupus erythematosus. Relationship with Raynaud's phenomenon, disease activity, inflammatory indices, anticardiolipin antibodies and corticosteroid therapy.
    Doria A; Ghirardello A; Boscaro M; Viero ML; Vaccaro E; Patrassi GM; Gambari PF
    Rheumatol Int; 1995; 14(5):207-11. PubMed ID: 7724997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lupus anticoagulant and history of thrombosis are not associated with persistent endothelial cell activation in systemic lupus erythematosus.
    Frijns CJ; Derksen RH; De Groot PG; Algra A; Fijnheer R
    Clin Exp Immunol; 2001 Jul; 125(1):149-54. PubMed ID: 11472438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating thrombomodulin in thrombotic thrombocytopenic purpura.
    Takahashi H; Hanano M; Wada K; Tatewaki W; Niwano H; Tsubouchi J; Nakano M; Nakamura T; Shibata A
    Am J Hematol; 1991 Nov; 38(3):174-7. PubMed ID: 1659186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis.
    Herrick AL; Illingworth K; Blann A; Hay CR; Hollis S; Jayson MI
    Ann Rheum Dis; 1996 Feb; 55(2):122-7. PubMed ID: 8712862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Interference of factor VIII excess on the detection of lupus anticoagulants by the activated partial thromboplastin time].
    Guermazi S; Gorgi Y; Ayed K; Dellagi K
    Pathol Biol (Paris); 1997 Jan; 45(1):28-33. PubMed ID: 9097843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The role of coagulation and fibrinolysis system in pathogenesis of toxemia of pregnancy].
    Nakabayashi M
    Nihon Sanka Fujinka Gakkai Zasshi; 1988 Aug; 40(8):1000-9. PubMed ID: 2855231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased fibrinolytic capacity and increased von Willebrand factor levels as indicators of endothelial cell dysfunction in patients with lupus anticoagulant.
    Nilsson TK; Löfvenberg E
    Clin Rheumatol; 1989 Mar; 8(1):58-63. PubMed ID: 2501064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma von Willebrand factor and thrombomodulin as markers of vascular disorders in patients undergoing regular hemodialysis therapy.
    Tomura S; Nakamura Y; Deguchi F; Chida Y; Ohno Y; Kodama S; Hayashi T; Suzuki K; Marumo F
    Thromb Res; 1990 May; 58(4):413-9. PubMed ID: 2162087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.